Kieran Murphy


Founder, President & Chairman of the Board

Dr Kieran Murphy is a physician and interventional neuroradiologist at Toronto Western Hospital in Toronto, Ontario. Dr Murphy is a pioneering clinician, translational researcher, and inventor, who has authored 176 peer reviewed publications and filed over 60 patents. He graduated from the Royal College of Surgeons in Dublin, Ireland, in 1986, completed his Radiology residency and Neuroradiology fellowship at the University of Michigan, Ann Arbor, and his Interventional Neuroradiology fellowship at University of Geneva. Prior to arriving in Toronto, he led the division of Interventional Neuroradiology at Johns Hopkins for 10 years.

Dr Murphy has filed 60 patents on new medical devices, pioneering new routes, techniques and approaches to complex spine, neurovascular and CSF pathologies. He has founded eight medical device companies, authored over 170 peer reviewed publications, published several textbooks and mentored over 100 Undergraduate, Masters, and PhD candidates, medical students, residents, fellows and staff physicians.

He launched and led UHN's International Health Care Program, successfully negotiating with the Kuwait, Bahrain, Qatar, and Saudi governments. From 2012-2016 he was Director of Clinical Faculty at the Techna Research Institute and has been heavily involved in developing a culture of innovation and entrepreneurial behaviour in the Techna and UHN faculty.

Dr Murphy’s current focus is on spine augmentation, radiofrequency ablation of bone metastatic disease, ozone in disk herniations, antioxidant use in radiation injury reduction, and global medical education. His hobbies include medical device development, historic airplanes, race car driving and taking things apart. He was awarded the Society of Interventional Radiology Innovator of the Year award in 2015 and was nominated for the 2016 Manning Innovation award. He received the 2019 American Society of Vascular Interventional Technology award for innovation and mentorship. He is Senior Technology Advisor to TVM private Equity based in Dubai, and Shore capital based in Chicago.

Mark Tarnopolsky

Mark Tarnopolsky, MD, PHD, FRCP(C)

Scientific Advisor

Dr. Mark Tarnopolsky holds an endowed chair at McMaster Children’s Hospital and Hamilton Health Sciences Foundation in Neuromuscular Diseases and is a Professor of Pediatrics and Medicine. He completed a PhD in cell biology and metabolism and residency training in Internal Medicine, Neurology and Physiatry. He is also a fellow of the American Academy of Electrodiagnostic Medicine.

Dr. Tarnopolsky has received numerous awards and recognitions, such as the David Green Award from the Muscular Dystrophy Association in 2005, the Barsky Lectureship for Excellence in Mitochondrial Medicine in 2007, and the Honour Award from the Canadian Society for Exercise Physiology in 2008. He has devoted his career to studying the impact of nutrition, exercise and drug therapies for genetic and aging-associated diseases.

David Simpson

David Simpson


Dave is a passionate and collaborative leader with 20+ years of successful experience in the business of delivering healthcare solutions. He has worked in multinational organizations such as Dow Corning and Johnson and Johnson. He has also led startups such as Kyphon and DFine through commercialization to IPO and acquisition.

He is known for a strong track record of industry-leading strategies, best-in-class commercial execution, and building a culture of collaboration and respect. Dave is dedicated to enhancing value through innovation, education, and superior service to customers.

Leonardo Bonifacio, PhD

Business Development Consultant

Kirsten Campbell

Director of Brand & Marketing

Board Members

Kieran Murphy

Robert Mitchell

Rohit Parehk

Cameron Piron

Martin Goldfarb

Scientific Advisory Board

John Kaufman

John Kaufman, MD, MS

Dr. Kaufman is director of the Dotter Institute and past president of the Society of Interventional Radiology. His clinical interests include aortic aneurysms, venous diseases, vascular malformations, and image guide treatment of liver cancers and uterine fibroids. He is also actively involved in clinical research in these areas.

He has authored or co-authored more than 200 publications including five textbooks. He is co-editor of the quarterly review journal Techniques in Vascular and Interventional Radiology and Associate Editor for the journal CardioVascular and Interventional Radiology. He has been honored as a Gold Medalist of the Society of Interventional Radiology, a Distinguished Fellow of the Cardiovascular and Interventional Radiology Society of Europe, and a Distinguished Alumnus of the Boston University School of Medicine.

Micheal Dake

Michael Dake, MD

Dr Michael Dake is a graduate of Harvard College and Baylor College of Medicine, where he completed an internship, residency and chief residency in internal medicine. He is board certified in internal medicine, pulmonary disease, diagnostic radiology, and vascular and interventional radiology.

Dr Dake has an international reputation for revolutionary work in improving vascular health to help treat debilitating diseases. He has published more than 300 peer-reviewed articles and more than 100 book chapters. His publications in Nature Medicine have been cited more than 1,000 times, and his papers in the New England Journal of Medicine have been referenced more than 1,500 times. Overall, the impact of Dr Dake's contributions to the medical literature have earned more than 30,000 citations, which puts him among the top scientists in his field. He holds 31 U.S. patents and has founded five companies.

Lindsay Machan

Lindsay Machan, MD

Dr. Machan is an interventional radiologist at the Vancouver Hospital and Associate Professor of Radiology at the University of British Columbia. His professional interests include endovascular vein therapy and local therapy of restenosis. He is co-founder of Angiotech Pharmaceuticals, a company which developed and licensed the paclitaxel coated stent, and Ikomed Technologies which is developing methods for reducing radiation dose during fluoroscopy.

Dr. Machan is a found of CIRA (Canadian Interventional Radiology Association), the co-author or Interventional Procedures, the largest selling interventional textbook worldwide, and sits on many commercial and scientific advisory boards for medical companies across Canada and the U.S. As well as being an active angel investor, he is heavily involved as a clinical practitioner, researcher and teacher at Vancouver Hospital, and has authored over 140 patents.